Sansure BiotechSHSE:688289 -0.35%67 Net Margin % is 11.37% as of Mar. 2026, which is 40% below its 10-year median of 18.90. GuruFocus rates SHSE:688289 with a GF Score™ of 67/100 and a GF Value™ of ¥20.52 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Sansure Biotech ranks better than 72.25% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sansure Biotech's Net Income for the
three
months ended in Mar. 2026 was ¥50 Mil. Sansure Biotech's Revenue for the
three
months ended in Mar. 2026 was ¥437 Mil. Therefore, Sansure Biotech's net margin for the quarter that ended in Mar. 2026 was 11.37%.
The historical rank and industry rank for Sansure Biotech's Net Margin % or its related term are showing as below:
SHSE:688289'
s Net Margin % Range Over the Past 10 Years
Min: -4.74 Med: 18.9 Max: 54.94
Current: 9.79
SHSE:688289's Net Margin % is ranked better than 72.25% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs SHSE:688289: 9.79
Sansure Biotech (SHSE:688289) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sansure Biotech Net Margin % Related Terms
Sansure Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688289 vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sansure Biotech (SHSE:688289) has a Net Margin % of 11.37% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sansure Biotech and its competitors. This is 40% below median its historical median of 18.90. According to the industry distribution chart, Sansure Biotech ranks #227 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 27.8%.
Is Sansure Biotech's Net Margin % too high?
Sansure Biotech's current Net Margin % of 11.37% is 40% below median its 10-year median of 18.90. The Medical Devices & Instruments industry median Net Margin % is 2.06. Sansure Biotech's value of 11.37% is 451.9% above this industry median. Based on the distribution chart, Sansure Biotech ranks #227 out of 818 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sansure Biotech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #227 out of 818 companies for Net Margin %. This puts Sansure Biotech in the upper half of its industry. The industry median Net Margin % is 2.06. Sansure Biotech's value of 11.37% is 451.9% above this benchmark. While the company's 10-year median is 18.90 vs. the industry median of 2.06, Sansure Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.06, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current Net Margin % of 11.37% is 451.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sansure Biotech and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current Net Margin % is 11.37%, which is 40% below median its own 10-year median of 18.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.52, compared to a current price of ¥14.07 — trading 31.4% below its estimated fair value. The current Net Margin % is 11.37%, which is 40% below median its 10-year median of 18.90 and 451.9% above the Medical Devices & Instruments industry median of 2.06. Sansure Biotech's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Net Margin % is 11.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥14.07 is trading 31.4% below its estimated GF Value™ of ¥20.52.
GuruFocus considers Sansure Biotech to be Possible Value Trap.
Key valuation signals for SHSE:688289:
Net Margin %: 11.37% (40% below median its 10-year median of 18.90)
GF Value™: ¥20.52 vs. price of ¥14.07 (31.4% below fair value)
Industry Position: 451.9% above the Medical Devices & Instruments median (#227 of 818)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
